計劃書編號B3P104833
尚未開始召募
2006-04-01 - 2007-03-31
Phase I
終止收納3
An Eight-Week Randomized, Double-Blind, Placebo Controlled , Parallel Group Proof of Concept Dose Ranging Study to Assess the Efficacy, Safety and Tolerability as well as the Pharmacokinetic Profile of Oral Solabegron (GW427353) 250mg, 125mg, and 50mg administered Twice Dailly vs Placebo, in Women with Overactive Bladder
-
試驗委託 / 贊助單位名稱
荷商葛蘭素史克藥廠股份有公司台灣分公司
-
臨床試驗規模
-
更新日期
2026/03/01
試驗主持人及試驗醫院
實際收案人數
0 終止收納
實際收案人數
0 終止收納
適應症
本試驗主要目的:比較每日口服兩劑solabegron 250mg, 125mg, 以及50mg相對於安慰劑, 對具有急迫性尿失禁及伴隨夜尿之頻尿, 但對非膀胱相關疼痛等症狀之膀胱過動症女性受試者的療效
試驗目的
The primary objective of this study is to compare the efficacy of solabegron 250mg, 125mg and 50mg administered twice daily, to that of placebo in female subjects with OAB including symptoms of urgency with urge incontinence and frequency which may be associated with nocturia, but without bladder related pain.
藥品名稱
主成份
Solabegron(GW427353)
劑型
劑量
25 and 100
評估指標
主要納入條件
試驗計畫預計收納受試者人數
-
台灣人數
15 人
-
全球人數
320 人
